Castle Biosciences recognized as one of the top 100 health technology companies in 2021

0

FRIENDSWOOD, Texas, August 30, 2021– (COMMERCIAL THREAD) – Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced its inclusion in The Health Technology Report List of the top 100 healthcare tech companies of 2021.

The companies selected for this year’s list include a variety of organizations, from well-known names to newer and fast-growing companies, in the fields of healthcare software, biotechnology, medical devices and large healthcare technologies. public. The winners were named and selected based on a thorough evaluation process. Among the main criteria considered were the quality of the product or service, customer adoption, caliber of the management team, organizational effectiveness and business growth, among other factors.

“Said the editorial team of the Healthcare Technology Report. “Organizations like Castle are making great strides in both modernizing and advancing healthcare. We look forward to Castle’s continued advancements in skin cancer testing.

“We are honored to be recognized as one of the Top 100 Health Technology Companies,” said Derek Maetzold, President and CEO of Castle Biosciences. “We are committed to transforming the management of skin cancer and other dermatological conditions through our innovative genomic testing. Since our inception in 2008, we have focused on improving patient care and outcomes through the application of emerging artificial intelligence techniques in molecular diagnostics. We continue to develop our line of tests for conditions with unmet clinical needs, accolades like these bolster our focus and reflect our position as a leader in dermatological testing. “

The full list can be found at https://thehealthcaretechnologyreport.com/.

About the Top 100 Healthcare Tech Companies of 2021

This year’s winners include a wide range of companies ranging from well-known names to relatively newer but rapidly growing companies. The diverse range of sophisticated products and services offered by these companies – from digital pharmacies to holistic patient care and from AI-powered robotics to digital healthcare payments – has not only led to the modernization of the healthcare industry. health, but also to a better future where health care is democratized for all. Advances in healthcare, whether through data and communications, research and clinical trials, or consumer offerings, have also helped create an environment where more promising healthcare alternatives are possible. The pioneering companies selected for this year’s list have one thing in common: they are revolutionizing the way we live and the way we manage one of the most important factors for all of us: our health.

About the Health Technology Report

The Healthcare Technology report provides market research and information, business news, updates on investment activities, and significant business developments related to the healthcare technology industry. Based in New York, the company is led by a seasoned team of editors, writers and media professionals very knowledgeable about health technology and the various companies, executives and investors that make up the industry.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatology diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx® -CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (myPath® Melanoma, DecisionDx® DiffDx ™ -Melanoma,) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information on Castle’s gene expression profile assays, visit www.CastleTestInfo.com.

Castle also has active research and development programs for testing in other dermatological diseases with high clinical need, including its test in development to predict systemic therapeutic response in patients with moderate to severe psoriasis, atopic dermatitis. and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix.

For more information visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Mélanome, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are registered trademarks of Castle Biosciences, Inc.

Forward-looking statements

The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safety port” created by these sections. These forward-looking statements include, but are not limited to, statements regarding our ability to modernize and advance healthcare, to continue to make advancements in healthcare. skin cancer testing, transforming the management of skin cancer and other dermatological conditions through our genomic testing, improving patient care and outcomes, expanding our test line and maintaining our position as a leader in testing The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “could”, “plans”, “projects”, “will”, “will” and similar expressions are intended to identify future- forward-looking statements, although not all forward-looking statements contain these identifying words. We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those of forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and efforts. to cope with its impact. about our business, our ability to achieve the above and the risks set out in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in our other documents filed with the SEC. Forward-looking statements speak only as of the date they are made, and we assume no obligation to update any forward-looking statements, except as required by law.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210830005071/en/

Contacts

Investor contact:
Camilla Zuckero
832-835-5158
[email protected]

Media contact:
Allison marshall
[email protected]


Source link

Leave A Reply

Your email address will not be published.